AEP-IN-3 (compound 18) is an orally active, potent and brain penetrant asparagine endopeptidase (AEP) inhibitor, with an IC50 of 7.8 ± 0.9 nM. AEP-IN-3 can be used for Alzheimer’s Disease (AD) research.
AEP-IN-3 (compound 18) has a bioavailability of 83% and a T1/2[1].
AEP-IN-3 (20 mg/kg, orally, BID, for 5 days) shows significantly inhibited activity of AEP in brain in TauP301L transgenic mice[1].
References:
[1]. Krummenacher D, et al. Discovery of Orally Available and Brain Penetrant AEP Inhibitors. J Med Chem. 2023 Dec 28;66(24):17026-17043.